Oscar Health, Inc. (NYSE:OSCR – Get Free Report) Director Sid Sankaran sold 139,635 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $6.25, for a total value of $872,718.75. Following the transaction, the director now owns 295,687 shares in the company, valued at approximately $1,848,043.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Oscar Health Price Performance
OSCR stock opened at $6.59 on Friday. The stock’s 50 day moving average price is $7.40 and its 200 day moving average price is $6.80. The firm has a market cap of $1.46 billion, a P/E ratio of -2.96 and a beta of 1.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.21 and a current ratio of 1.21. Oscar Health, Inc. has a 1 year low of $2.05 and a 1 year high of $9.89.
Oscar Health (NYSE:OSCR – Get Free Report) last announced its earnings results on Tuesday, August 8th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.26. The firm had revenue of $1.52 billion for the quarter, compared to analysts’ expectations of $1.38 billion. Oscar Health had a negative return on equity of 49.14% and a negative net margin of 9.55%. Oscar Health’s quarterly revenue was up 49.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.53) EPS. On average, sell-side analysts expect that Oscar Health, Inc. will post -1.45 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oscar Health
Analysts Set New Price Targets
OSCR has been the topic of several recent analyst reports. The Goldman Sachs Group boosted their target price on Oscar Health from $5.50 to $7.50 and gave the stock a “neutral” rating in a research report on Thursday, August 10th. Morgan Stanley boosted their target price on Oscar Health from $5.00 to $7.50 and gave the stock an “equal weight” rating in a research report on Wednesday, August 30th. Bank of America raised Oscar Health from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $5.40 to $8.75 in a research note on Tuesday, June 6th. Finally, Credit Suisse Group boosted their price target on Oscar Health from $7.00 to $8.50 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.46.
Oscar Health Company Profile
Oscar Health, Inc operates as a health insurance in the United States. The company offers Individual and Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payors directly enable their shift to value-based care It also provides reinsurance products.
- Five stocks we like better than Oscar Health
- What Are Meme Stocks and Are They Viable Investments?
- These 3 Wood Stocks are about to go on Discount
- What is Insider Trading? What You Can Learn from Insider Trading
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- What Is Dividend Yield and How Do You Calculate It?
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.